US20030055214A1 - Guanidinylation reagents - Google Patents
Guanidinylation reagents Download PDFInfo
- Publication number
- US20030055214A1 US20030055214A1 US10/137,119 US13711902A US2003055214A1 US 20030055214 A1 US20030055214 A1 US 20030055214A1 US 13711902 A US13711902 A US 13711902A US 2003055214 A1 US2003055214 A1 US 2003055214A1
- Authority
- US
- United States
- Prior art keywords
- guanidine
- boc
- protected
- group
- cbz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 17
- -1 N-protected guanidines Chemical class 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 11
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- RANFIWPOSLNLHW-UHFFFAOYSA-N benzyl n-[n-[(2-methylpropan-2-yl)oxycarbonyl]-n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OCC1=CC=CC=C1 RANFIWPOSLNLHW-UHFFFAOYSA-N 0.000 claims description 5
- 150000003335 secondary amines Chemical class 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 3
- 150000003333 secondary alcohols Chemical class 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000075 primary alcohol group Chemical group 0.000 claims 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 0 [1*]OC(C)=O Chemical compound [1*]OC(C)=O 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- 229960004198 guanidine Drugs 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 150000002357 guanidines Chemical class 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- GOQZIPJCBUYLIR-UHFFFAOYSA-N tert-butyl n-[n-[(2-methylpropan-2-yl)oxycarbonyl]-n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OC(C)(C)C GOQZIPJCBUYLIR-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 6
- 229960000789 guanidine hydrochloride Drugs 0.000 description 6
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 6
- XZGNHTJSFCBWHG-UHFFFAOYSA-N tert-butyl n-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(NC(=O)OC(C)(C)C)=NC(=O)OC(C)(C)C XZGNHTJSFCBWHG-UHFFFAOYSA-N 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- KOFWAGBYGLPTBW-UHFFFAOYSA-N [H]N(C)/C(=N/P(P)P)N([H])PP Chemical compound [H]N(C)/C(=N/P(P)P)N([H])PP KOFWAGBYGLPTBW-UHFFFAOYSA-N 0.000 description 4
- 150000001483 arginine derivatives Chemical class 0.000 description 4
- HXXLPXYJKOPUDG-UHFFFAOYSA-N benzyl (ne)-n-[amino-[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=N)NC(=O)OCC1=CC=CC=C1 HXXLPXYJKOPUDG-UHFFFAOYSA-N 0.000 description 4
- WUPOXNUSSFCSGV-UHFFFAOYSA-N benzyl n-[amino(phenylmethoxycarbonylamino)methylidene]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(=N)NC(=O)OCC1=CC=CC=C1 WUPOXNUSSFCSGV-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VPWFNCFRPQFWGS-UHFFFAOYSA-N tert-butyl n-[amino-[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(N)=NC(=O)OC(C)(C)C VPWFNCFRPQFWGS-UHFFFAOYSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000007960 acetonitrile Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- FZOCFRPFPKJHHP-UHFFFAOYSA-N benzyl n-(diaminomethylidene)carbamate Chemical compound NC(N)=NC(=O)OCC1=CC=CC=C1 FZOCFRPFPKJHHP-UHFFFAOYSA-N 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- JMNNQFRFFPDLTA-UHFFFAOYSA-N 2-(trifluoromethylsulfonyl)guanidine Chemical class NC(=N)NS(=O)(=O)C(F)(F)F JMNNQFRFFPDLTA-UHFFFAOYSA-N 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- GULYZQMNPGSYSG-CJKZHBTQSA-N C/N=C(/C)N(C)CC[C@@H](C)NC.C/N=C(/C)N(C)CC[C@H](NC)C(=O)OC.C/N=C(/C)NC.C/N=C(/C)NC.CN[C@@H](CCO)C(=O)OC.CN[C@H](C)CCO Chemical compound C/N=C(/C)N(C)CC[C@@H](C)NC.C/N=C(/C)N(C)CC[C@H](NC)C(=O)OC.C/N=C(/C)NC.C/N=C(/C)NC.CN[C@@H](CCO)C(=O)OC.CN[C@H](C)CCO GULYZQMNPGSYSG-CJKZHBTQSA-N 0.000 description 1
- HPXVYNDNJKQROU-DAECCGKTSA-N C/N=C(/N(C)C)N(C)CCC[C@@H](C)NC.C/N=C(\NC)N(C)C.CC/C(=N/C)NC.CN=C(NC)NC.CN[C@H](C)CCCO.CO Chemical compound C/N=C(/N(C)C)N(C)CCC[C@@H](C)NC.C/N=C(\NC)N(C)C.CC/C(=N/C)NC.CN=C(NC)NC.CN[C@H](C)CCCO.CO HPXVYNDNJKQROU-DAECCGKTSA-N 0.000 description 1
- XCMPBWRSXDTXRB-RVYSEXHFSA-N C/N=C(/NC)NCCCC[C@H](NC)C(=O)O.CN[C@@H](CCCCN)C(=O)O Chemical compound C/N=C(/NC)NCCCC[C@H](NC)C(=O)O.CN[C@@H](CCCCN)C(=O)O XCMPBWRSXDTXRB-RVYSEXHFSA-N 0.000 description 1
- YBUHZNASJMWDBN-UHFFFAOYSA-N C=C(C)C.C=C(C)NC.C=C(C)NC.CC(=N)N1C=CC=N1.CC(C)=NS(=O)(=O)C(F)(F)F.CNC(C)=N Chemical compound C=C(C)C.C=C(C)NC.C=C(C)NC.CC(=N)N1C=CC=N1.CC(C)=NS(=O)(=O)C(F)(F)F.CNC(C)=N YBUHZNASJMWDBN-UHFFFAOYSA-N 0.000 description 1
- ABPHFZBYSBLZGM-UHFFFAOYSA-N CC(=O)NC(=N)NC(C)=O.CC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(C)=O Chemical compound CC(=O)NC(=N)NC(C)=O.CC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(C)=O ABPHFZBYSBLZGM-UHFFFAOYSA-N 0.000 description 1
- PXVKALOBIZEMFV-UHFFFAOYSA-N CC(C)(C)OC(=O)NC(=N)NC(=O)OC(C)(C)C.CC(C)(C)OC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OC(C)(C)C.O=S(=O)(OS(=O)(=O)C(F)(F)F)C(F)(F)F Chemical compound CC(C)(C)OC(=O)NC(=N)NC(=O)OC(C)(C)C.CC(C)(C)OC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OC(C)(C)C.O=S(=O)(OS(=O)(=O)C(F)(F)F)C(F)(F)F PXVKALOBIZEMFV-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical class OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical class CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- IDJQBTGOPMPELE-UHFFFAOYSA-N [H]CNC(CCNC(=N)N)C(=O)CC Chemical compound [H]CNC(CCNC(=N)N)C(=O)CC IDJQBTGOPMPELE-UHFFFAOYSA-N 0.000 description 1
- WWHKRGXODSPHJD-UHFFFAOYSA-N [H]N(C)/C(=N/S(=O)(=O)C(F)(F)F)N([H])PP Chemical compound [H]N(C)/C(=N/S(=O)(=O)C(F)(F)F)N([H])PP WWHKRGXODSPHJD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 1
- GLZHTZVKRCUQRB-UHFFFAOYSA-N benzyl n-[n-phenylmethoxycarbonyl-n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OCC1=CC=CC=C1 GLZHTZVKRCUQRB-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 238000003408 phase transfer catalysis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- XJJPBWGZFXYDPI-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrrolidin-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1CCCC1 XJJPBWGZFXYDPI-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
- C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to reagents and methods for the synthesis of organic molecules containing a guanidine group. It relates particularly to reagents useful for introducing a protected guanidine group into a molecule.
- Guanidine-containing bioactive molecules are now significant targets for drug design and discovery.
- the guanidine moiety in the bioactive compound frequently occurs in arginine-containing polypeptide chains which may comprise the entire biomolecule or exist as an incorporated moiety.
- Arginine together with lysine, another amino acid with a positively charged side chain, plays an important role in biologically active proteins and peptides.
- Various arginine analogues and derivatives have been synthesized and incorporated into peptides and peptidomimetics to study the structure-activity relationships of arginine-containing molecules. These residues are frequently the critical amino acid residues in peptidomimetics.
- FIG. 1 X-ray structure of di-Boc-trifl-guanidine
- FIG. 2 Comparison of N-,N′-di-Boc-N′′-triflyl-guanidine with two commercially available guanidinylation reagents. All three reactions were carried out in an NMR-instrument and the formation of product was followed by integration of the signals of the benzylic CH 2 -groups. In all reactions the concentration of the guanidinylating agent was 100 mM and the concentration of benzylamine was 90 mM. Benzene-d6 was used as a solvent. Similar results were obtained in deuterated chloroform and in deuterated acetonitrile.
- alkyl refers to a monovalent straight or branched chain radical of from one to ten carbon atoms, including, but not limited to methyl, ethyl, n propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, and the like.
- Alkyl also represents cyclic radicals, including, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- perfluoroalkyl refers to a monovalent straight chain radical of from one to four carbon atoms, in which all hydrogen atoms are substituted by fluorine.
- a typical perfluorinated alkyl group is the trifluoromethyl group.
- aryl when used alone refers to an aromatic radical whether or not fused. Preferred aryl groups include phenyl, naphthyl, biphenyl and the like. Aryl also refers to heteroaromatic groups including, but not limited to, furanyl, pyrrolyl, thienyl, pyrazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, indolyl, and the like.
- substituted aryl denotes an aryl group substituted with one, two or three substituents chosen from halogen, cyano, nitro, C1-C10 alkyl, C1-C10-alkyloxy, trifluoromethyl, alkyloxycarbonyl, and the like. Examples of such groups are 4 chlorophenyl, 2-methylphenyl, and 3-ethoxyphenyl.
- arylalkyl means one, two or three aryl groups having the designated number of carbons, appended to an alkyl chain having the number of carbons designated.
- a typical arylalkyl group is the benzyl group.
- alkenyl refers to a straight or branched chain group of from two to ten carbon atoms containing a carbon-carbon double bond, including, but not lirnited to allyl, vinyl, and the like.
- Compounds of type I comprise guanidines with three symmetrically arranged electron-withdrawing protecting groups (P) and have the structure
- P 1 , P 2 and P 3 are the same or different urethane protecting groups, each having the general structure
- R is a substituted or unsubstituted alkyl or aryl group or heterocyclic group.
- P is chosen from urethane protecting groups which are conveniently removable. These groups are available in an almost limitless number. Reviews of urethane groups and their use in peptide synthesis are provided by Geiger, R. and König, W. in “The Peptides” (Gross, E. Meienhofer, I., eds) Vol.3, p3. New York, N.Y. 1981 and in Winsch, E. Methoden der Org. Chem. (Houben-Weyl) Vol. 15/1 (Wünsch, E.,ed.), p.46, Stuttgart: Thieme 1974. Particularly preferred are the urethane groups containing a substituted or unsubstituted benzylic carbon atom.
- the protected type I guanidines of the invention are weak acids and can be used to guanidinylate primary or secondary alcohols in a Mitsunobu-reaction to produce triprotected alkyl guanidines (scheme 1).
- the product of such a reaction still possesses one acidic hydrogen atom which can be exploited in a second Mitsunobu-reaction to produce protected dialkylated guanidines.
- R 1 , R 2 , R 3 , and R 4 can be hydrogen or any substituted or unsubstituted alkyl, alkenyl, aryl, or arylalkyl group as described earlier.
- R 1 and R 2 (and/or R 3 and R 4 ) may be part of a ring structure as in cyclopropanol, cyclobutanol, cyclopentanol, cyclohexanol and the like.
- Compounds of type II comprise guanidines with a sulfonyl group in addition to two urethane protecting groups, having the structure
- P 1 and P 2 are as defined above and R 1 is a substituted or unsubstituted alkyl or aryl group. Perfluoroalkyl groups are preferred. Type II protected guanidines react with primary or secondary amines to produce diprotected alkyl guanidines (scheme 2).
- R 2 and R 3 can be hydrogen or any substituted or unsubstituted alkyl, alkenyl, aryl, or arylalkyl group as described earlier.
- R 2 and R 3 may be part of a ring structure as in aziridine, azetidine, pyrrolidine, piperidine, morpholine, and the like.
- P is Boc or Cbz and R 1 is phenyl, 4-methyiphenyl, methyl, or trifluoromethyl.
- R 1 is phenyl, 4-methyiphenyl, methyl, or trifluoromethyl.
- Analogs with other protecting groups such as Troc, Alloc or Moz at the P-position are expected to show the same kind of reaction.
- a general route towards symmetrical trisubstituted guanidines is shown in scheme 3.
- the introduction of the first two protecting groups into guanidine hydrochloride is accomplished in one step. Yields between 50 and 80% are usually obtained.
- the diprotected guanidine is then treated with two equivalents of sodium hydride under anhydrous conditions. Acylation of the resulting anion then completes the synthesis.
- R is benzyl, 2-chlorobenzyl, 4-methoxylbenzyl, 2,2,2-trichloroethyl, allyl, or tert-butyl and
- X is chloro, azido, succinimidyloxy, or alkoxycarbonyloxy.
- symmetrical triprotected guanidines can be synthesized in one step from guanidine hydrochloride by phase transfer catalysis (scheme 4).
- Guanidinylation agents of type II can be synthesized by deprotonation of diprotected guanidines with sodium hydride in an inert solvent and reaction of the resulting anion with a sulfonyl chloride (scheme 5).
- sulfonyl chlorides instead of sulfonyl chlorides, sulfonyl anhydrides can be used as shown in the synthesis of N-,N′-di-Cbz-N-triflyl-guanidine (scheme 6).
- triethylamine can be used as a base instead of sodium hydride.
- An example is given in scheme 7 with the synthesis of N-,N′-di-Boc-N′′-triflyl-guanidine.
- Guanidinylation reagents of type I react with primary and secondary alcohols in a Mitsunobu-reaction to produce protected alkylated guanidines. This is exemplified in the synthesis of several orthogonally protected arginine analogs (scheme 8) from suitable precursor molecules.
- the reactions with N-,N′-,N′′-tri-Boc-guanidine are preferably carried out in refluxing THF and yields of up to 70% can be obtained. If N-,N′-,N′′-tri-Cbz-guanidine is used as the guanidinylating species, the reaction can be carried out at room temperature. In addition, the yields are usually somewhat higher (up to 86%) than in comparable reactions with N-,N′-,N′′-tri-Boc-guanidine.
- N-,N′-Di-Boc-N′′-triflyl-guanidine reacts rapidly and under mild conditions with primary (scheme 10) and secondary amines (scheme 11). The reactions are carried out at room temperature and are usually complete within 1 h. Succesful guanidinylation reactions have been performed in a wide range of solvents such as benzene, chloroform, or dichloromethane, acetonitrile or DMSO. Unpolar solvents such as benzene, chloroform, or dichloromethane are preferred.[U6] Compounds that are insoluble in one of the preferred solvents can in many cases be converted into a more soluble derivative which can then be successivefully guanidinylated.
- solvents such as benzene, chloroform, or dichloromethane
- N- ⁇ -Fmoc-lysine is first silylated with MSTFA (N-methyl-N-trimethylsilyl-trifluoroacetarnide) to generate a derivative that is soluble in dichloromethane.
- MSTFA N-methyl-N-trimethylsilyl-trifluoroacetarnide
- This derivative is then guanidinylated in the same pot with N-,N′-di-Boc-N′′-triflyl-guanidine.
- the silyl-groups used to solubilize the starting material are removed again during the workup procedure.
- N-,N′-Di-Cbz-N′′-triflyl-guanidine is an excellent reagent for the guanidinylation of unreactive aromatic amines.
- the reaction with aniline is complete after 1 h at room temperature (scheme 12).
- N-,N′-N′′-tri-Cbz-guanidine (2.07 g, 90%) is obtained as a white powder: mp: 111-112° C.; 1 H NMR (360 MHz, DMSO-d 6 ) ⁇ 10.55, (s, 2H), 7.36 (s, 10H), 5.22 (br s, 6H); FAB-MS m/e (relative intensity) 506 (5, M-H + +2Na + ), 484 (100, M+Na + ), 462 (24, M+H + ); Anal. Calc. for C, 65.07%; H, 5.02%;.N, 9.11%; Found: C, 64.89%; H, 4.74%;.N, 8.82%.
- reaction mixture is stirred for 18 h at 45° C.
- the solution is then cooled to room temperature, and hexanes (100 ml) is added.
- a precipitate of excess N-,N′-N′′-tri-Boc-guanidine forms which is collected by filtration on a Buechner-funnel and washed with a mixture of THF/hexanes 1:1.
- 1,4-Dioxane (50 ml) is added to a solution of guanidine hydrochloride (2.39 g, 25 mmol) and sodium hydroxide (4.0 g, 0.1 mol) in water (25 ml) and the resulting mixture is cooled to 0° C.
- Di-tert-butyl-pyrocarbonate (12.0 g, 55 mmol) is added in one portion while stirring.
- the reaction mixture is allowed to warm to room temperature within 2 h. After stirring for 20 h the mixture is concentrated in vacuo to one third of its original volume.
- the resulting suspension is diluted with water (50 ml) and extracted three times with ethyl acetate (5 ml each).
- N-,N′-di-Boc-guanidine (3.84 g, 59%) is obtained as a colorless powder: mp: 144° C.; 1 H NMR (360 MHz, DMSO-d 6 ) ⁇ 10.42 (br s, 1H), 8.47 (br s, 2H), 1.39 (s, 18H); FAB-MS m/e (relative intensity) 260 (50, M+H + ), 204 (48), 148 (100); Anal. Calc. for: C, 50.95%; H, 8.16%;.N, 16.21%; Found: C, 50.83%; H, 8.04%;.N, 16.26%.
- N-,N′-Di-Cbz-guanidine (9.85 g, 75%) is obtained as colorless crystals: mp: 149-150° C.; H NMR (360 MHz, DMSO-d 6 ) ⁇ 10.88 (br s, 1H), 8.67 (br s, 2H), 7.40-7.25 (m, 10H), 5.10 (s, 4H); Anal. Calc. for C, 62.38%; H, 5.23%;.N, 12.84%. Found: C, 62.26%; H, 5.01%;.N, 12.79%.
- N-N′-Di-Cbz-N′′′-trifluoromethanesulfonyl guanidine (1.58 g, 69%) is obtained as a pale oil that crystallizes in vacuo: mp: 74-75° C.; 1 H NMR (360 MHz, DMSO-d 6 ) ⁇ 11.55 (br s, 2H), 7.45-7.28 (m, 10H), 5.20 (s, 4H); Electrospray-MS m/le (relative intensity) 498 (30, M+K + ), 482 (100, M+Na + ), 460 (2, M+H + ); Anal. Calc.
- 1,4-Dioxane (20 ml) is added to a solution of guanidine hydrochloride (0.96 g, 10 mmol) and sodium hydroxide (0.8 g, 20 mmol) in water (10 ml) and the resulting mixture is cooled to 0° C.
- Benzyloxycarbonyl chloride (1.1 ml, 7.7 mmol) is added dropwise with vigorous stirring over a period of 10 min. After the addition is completed, the ice-bath is removed and stirring is continued for 1 h at room temperature. The mixture is concentrated in vacuo to one third of its original volume and extracted three times with ethyl acetate (20 ml each).
- N-Boc-N′-Cbz-guanidine (1.44 g, 82%) is obtained as a white powder: mp: 125-126° C.; 1 H NMR (360 MHz, DMSO-d 6 ) ⁇ 10.59 (br s, 1H), 8.69 (br s, 1H), 8.50 (br s, 1H), 7.40-7.25 (m, 5H), 5.04 (s, 2H), 1.42 (s, 9H).
- N-Boc-N′-Cbz-N′′-trifluoromethanesulfonyl-guanidine (699 mg, 82%) is obtained as a pale oil that crystallizes upon drying in vacuo: mp: 95-97° C.; 1 H NMR (360 MHz, DMSO-d 6 ) ⁇ 11.49 (br s, 1H), 11.17 (br s, 1H), 7.40 (m, 5H), 5.21 (s, 1H), 1.43 (s, 9H); FAB-MS m/e (relative intensity) 448 (23, M+Na + ), 426 (44, M+H + ), 329 (5), 370 (100), 348 (15), 326 (15).
- N-N′-Di-Boc-N′′-trifluoromethanesulfonyl-guanidine (235 mg, 0.6 mmol) is added to a solution of pyrrolidine (0.042 ml, 0.5 mmol) and triethyl amine (0.083 ml) in chloroform (1 ml). After stirring for 4 h at room temperature, the product is isolated by flash chromatography on silica gel (eluent: ethyl acetate-hexane 2:3).
- N-N′-di-Boc-N′′-phenyl-guanidine (198 mg, 98%) is obtained as a colorless oil that crystallizes upon drying in vacuo: mp: 105-108° C.; 1 H NMR (360 MHz, DMSO-d 6 ) ⁇ 11.34 (br s, 1H), 9.99 (s, 1H), 7.56-7.11 (m, 15H), 5.23 (s, 2H), 5.02(s, 1H).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
Abstract
Trisubstituted N-protected guanidines and methods for use as guanidinylating reagents to yield N-protected guanidine derivatives.
Description
- The invention relates to reagents and methods for the synthesis of organic molecules containing a guanidine group. It relates particularly to reagents useful for introducing a protected guanidine group into a molecule.
- Many natural compounds that bear a guanidine function have biological activity that make them useful as pharmaceuticals. Among these compounds are antimicrobials, antifungals, antivirals, neurotoxins, hormones, and agents that act as agonists or antagonists to biological signals. A review of these natural products is presented in Progress in the Chemistry of Organic Natural Products (1995) 66:119 and Berlinck, R. G. S. (1996) Nat. Prod. Reports 13(5):377409. Much effort has been directed to developing routes for preparing these compounds or their analogues synthetically.
- Guanidine-containing bioactive molecules, particularly the analogs or derivatives of the natural products, are now significant targets for drug design and discovery. The guanidine moiety in the bioactive compound frequently occurs in arginine-containing polypeptide chains which may comprise the entire biomolecule or exist as an incorporated moiety. Arginine, together with lysine, another amino acid with a positively charged side chain, plays an important role in biologically active proteins and peptides. Various arginine analogues and derivatives have been synthesized and incorporated into peptides and peptidomimetics to study the structure-activity relationships of arginine-containing molecules. These residues are frequently the critical amino acid residues in peptidomimetics.
- A completely satisfactory guanidinylating reagent has not yet been achieved. More effective guanidinylation reagents are useful in improving the synthesis of arginine analogues and other guanidine-containing molecules.
- FIG. 1: X-ray structure of di-Boc-trifl-guanidine
- FIG. 2: Comparison of N-,N′-di-Boc-N″-triflyl-guanidine with two commercially available guanidinylation reagents. All three reactions were carried out in an NMR-instrument and the formation of product was followed by integration of the signals of the benzylic CH2-groups. In all reactions the concentration of the guanidinylating agent was 100 mM and the concentration of benzylamine was 90 mM. Benzene-d6 was used as a solvent. Similar results were obtained in deuterated chloroform and in deuterated acetonitrile.
- Definitions
- The term “alkyl” used herein refers to a monovalent straight or branched chain radical of from one to ten carbon atoms, including, but not limited to methyl, ethyl, n propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, and the like. Alkyl also represents cyclic radicals, including, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- The term “perfluoroalkyl” as used herein refers to a monovalent straight chain radical of from one to four carbon atoms, in which all hydrogen atoms are substituted by fluorine. A typical perfluorinated alkyl group is the trifluoromethyl group.
- The term “aryl” when used alone refers to an aromatic radical whether or not fused. Preferred aryl groups include phenyl, naphthyl, biphenyl and the like. Aryl also refers to heteroaromatic groups including, but not limited to, furanyl, pyrrolyl, thienyl, pyrazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, indolyl, and the like.
- The term “substituted aryl” denotes an aryl group substituted with one, two or three substituents chosen from halogen, cyano, nitro, C1-C10 alkyl, C1-C10-alkyloxy, trifluoromethyl, alkyloxycarbonyl, and the like. Examples of such groups are 4 chlorophenyl, 2-methylphenyl, and 3-ethoxyphenyl.
- The term “arylalkyl” means one, two or three aryl groups having the designated number of carbons, appended to an alkyl chain having the number of carbons designated. A typical arylalkyl group is the benzyl group.
- The term “alkenyl” refers to a straight or branched chain group of from two to ten carbon atoms containing a carbon-carbon double bond, including, but not lirnited to allyl, vinyl, and the like.
- Guanidinylation Reagents
-
-
- wherein R is a substituted or unsubstituted alkyl or aryl group or heterocyclic group.
- P is chosen from urethane protecting groups which are conveniently removable. These groups are available in an almost limitless number. Reviews of urethane groups and their use in peptide synthesis are provided by Geiger, R. and König, W. in “The Peptides” (Gross, E. Meienhofer, I., eds) Vol.3, p3. New York, N.Y. 1981 and in Winsch, E. Methoden der Org. Chem. (Houben-Weyl) Vol. 15/1 (Wünsch, E.,ed.), p.46, Stuttgart: Thieme 1974. Particularly preferred are the urethane groups containing a substituted or unsubstituted benzylic carbon atom. Urethane-type protecting groups having a benzylic carbon atom are described by Bodanszky, M. (1984) Principles of Peptide Synthesis Chap. III Sec. C, Springer-Verlag, New York 1984. Such groups are removable by hydrogenolysis and by acidolysis, as well as by base-induced β-elimination. Preferably, the protecting group P is an alkyloxylcarbonyl group such as Boc (P=tert-butyloxycarbonyl), Cbz (P=benzyloxycarbonyl), Alloc (P=allyloxycarbonyl), Troc (P=2,2,2-trichloroethyloxycarbonyl), or Moz (P=4-methoxybenzyloxycarbonyl). The protecting groups Boc and Cbz are particularly preferred.
- The protected type I guanidines of the invention are weak acids and can be used to guanidinylate primary or secondary alcohols in a Mitsunobu-reaction to produce triprotected alkyl guanidines (scheme 1). The product of such a reaction still possesses one acidic hydrogen atom which can be exploited in a second Mitsunobu-reaction to produce protected dialkylated guanidines.
- R1, R2, R3, and R4 can be hydrogen or any substituted or unsubstituted alkyl, alkenyl, aryl, or arylalkyl group as described earlier. R1 and R2 (and/or R3 and R4) may be part of a ring structure as in cyclopropanol, cyclobutanol, cyclopentanol, cyclohexanol and the like.
-
-
- R2 and R3 can be hydrogen or any substituted or unsubstituted alkyl, alkenyl, aryl, or arylalkyl group as described earlier. R2 and R3 may be part of a ring structure as in aziridine, azetidine, pyrrolidine, piperidine, morpholine, and the like.
- Preferably, P is Boc or Cbz and R1 is phenyl, 4-methyiphenyl, methyl, or trifluoromethyl. Analogs with other protecting groups such as Troc, Alloc or Moz at the P-position are expected to show the same kind of reaction. Because of the exceptionally strong electron-withdrawing character of the triflyl group, the triflyl-guanidines (R1=trifluoromethyl) are the most reactive among the compounds synthesized so far and these are therefore preferred. They have been shown to be superior to previously described guanidinylating reagents.
- Synthesis of Guanidinylation Agents of Type I
- A general route towards symmetrical trisubstituted guanidines is shown in scheme 3. The introduction of the first two protecting groups into guanidine hydrochloride is accomplished in one step. Yields between 50 and 80% are usually obtained. The diprotected guanidine is then treated with two equivalents of sodium hydride under anhydrous conditions. Acylation of the resulting anion then completes the synthesis. Preferably, R is benzyl, 2-chlorobenzyl, 4-methoxylbenzyl, 2,2,2-trichloroethyl, allyl, or tert-butyl and X is chloro, azido, succinimidyloxy, or alkoxycarbonyloxy.
-
- Synthesis of Guanidinylation Agents of Type II
- Guanidinylation agents of type II can be synthesized by deprotonation of diprotected guanidines with sodium hydride in an inert solvent and reaction of the resulting anion with a sulfonyl chloride (scheme 5). This method was successfully applied in the synthesis of N-,N′-di-Cbz-N″-methylsulfonyl-guanidine (R1=benzyl, R2=Methyl), N-,N′-di-Cbz-N″-phenylsulfonyl-guanidine (R1=benzyl, R2=phenyl), and N-,N′-di-Cbz-N″-tosyl-guanidine (R1=benzyl, R2=tosyl).
-
-
- Reactions of Guanidinylation Agents of Type I
- Guanidinylation reagents of type I react with primary and secondary alcohols in a Mitsunobu-reaction to produce protected alkylated guanidines. This is exemplified in the synthesis of several orthogonally protected arginine analogs (scheme 8) from suitable precursor molecules. The reactions with N-,N′-,N″-tri-Boc-guanidine are preferably carried out in refluxing THF and yields of up to 70% can be obtained. If N-,N′-,N″-tri-Cbz-guanidine is used as the guanidinylating species, the reaction can be carried out at room temperature. In addition, the yields are usually somewhat higher (up to 86%) than in comparable reactions with N-,N′-,N″-tri-Boc-guanidine.
- Many biologically interesting guanidines contain two different alkyl substituents connected to two different N-atoms of the guanidine nucleus. Compounds of this type are accessible from triprotected guanidines by two consecutive Mitsunobu-reactions. An example is given in scheme 9 with the synthesis of protected derivative of ω-methyl-arginine, an important inhibitor of nitric oxide synthethase.
- Reactions of Guanidinylation Agents of Type II
- N-,N′-Di-Boc-N″-triflyl-guanidine reacts rapidly and under mild conditions with primary (scheme 10) and secondary amines (scheme 11). The reactions are carried out at room temperature and are usually complete within 1 h. Succesful guanidinylation reactions have been performed in a wide range of solvents such as benzene, chloroform, or dichloromethane, acetonitrile or DMSO. Unpolar solvents such as benzene, chloroform, or dichloromethane are preferred.[U6] Compounds that are insoluble in one of the preferred solvents can in many cases be converted into a more soluble derivative which can then be succesfully guanidinylated. This is demonstrated in
scheme 10 with the synthesis of a homoarginine derivative from N-α-Fmoc-lysine. In this procedure N-α-Fmoc-lysine is first silylated with MSTFA (N-methyl-N-trimethylsilyl-trifluoroacetarnide) to generate a derivative that is soluble in dichloromethane. This derivative is then guanidinylated in the same pot with N-,N′-di-Boc-N″-triflyl-guanidine. The silyl-groups used to solubilize the starting material are removed again during the workup procedure. Other protected diamino acids such as N-α-Fmoc-ornithine, N-α-Fmoc-2,4-diamino-butyric acid or N-α-Fmoc-2,3-diamino-propionic acid are expected to show the same kind of reaction The arginine analogues produced by this methodology are orthogonally protected and can be used for peptide coupling reactions without further modifications. -
-
- Guanidinylations with N-,N′-Di-Boc-N″-Triflyl-Guanidine on Solid Phase
- Reactions on solid phase are usually slower than comparable reactions in solution. Much effort is currently directed to adapt useful chemical reactions to the unique conditions of solid phase synthesis. Such optimized reactions are especially important for the construction of chemical libraries by parallel and combinatorial methods.
- The high reactivity of N-,N′-di-Boc-N″-triflyl-guanidine allows guanidinylations on solid phase to be performed successfully. This is demonstrated by the conversion of an ornithine residue in a peptide sequence to arginine (scheme 13). The peptide was assembled on a PAM-resin (PAM: phenylacetamidomethyl) by standard methods. Omithine, the ε-amino group protected by Fmoc, was incorporated in place of arginine. After complete assembly of the sequence the Fmoc-group on the ornithine side chain was removed selectively and the free amino group was guanidinylated with N-,N′-di-Boc-N″-triflyl-guanidine. The unprotected arginine-containing peptide was then obtained after removal of the Boc-groups and cleavage of the peptide from the resin with HF. Analysis of the crude peptide by FAB-MS indicated a homogeneous product. No peaks suggesting incomplete guanidinylation could be detected.
-
- Comparison of N-,N′-Di-Boc-N′-triflyl-Guanidine With Other Guanidinylating Reagents
- The guanidinylation of benzylarnine in benzene was chosen as a model reaction to compare two commercially available guanidinylating agents with N-,N′-di-Boc-N″-triflyl-guanidine (scheme 14). All three reactions were carried out in an NMR-instrument and the formation of product was followed by integration of the signals of the benzylic CH2-groups. Under the conditions chosen, N-,N′-di-Boc-N″-triflyl-guanidine proved superior to the other reagents. Similar results were obtained in deuterated chloroform and ind deuterated acetonitrile.
- Potassium hydroxide pellets (2.81 g, 50 mmol) and sodium carbonate (5.30 g, 50 mmol) are finely ground in a mortar and transferred into a 250 ml round bottomed flask equipped with a magnetic stirrer and a reflux condenser. DMSO (50 ml) is added and the resulting suspension is stirred for 5 min at room temperature. Guanidine hydrochloride (4.78 g, 50 mmol) is added and the mixture is again stirred for 5 min After the addition of di-tert-butyl-dicarbonate (51.7 ml, 225 mmol) the mixture is stirred for 60 h at 40° C. The colorless precipitate obtained by pouring the cold reaction mixture into 11 water is collected by filtration on Buechner funnel, washed with water and dried overnight in vacuo. Recrystallization from acetonitrile yields colorless needles (14.9 g, 83%): mp 147-150° C. (dec);1H NMR (360 MHz, CDCl3) δ 1.48 (s, 27H); FAB-MS m/e (relative intensity) 360 (100, M+H+), 304 (34), 260 (10), 248 (74); Anal. Calc. for: C, 53.47%; H, 8.13%;.N, 11.69%; Found: C, 53.48%; H, 8.34%;.N, 11.86%.
- Sodium hydride (400 mg, 60% dispersion in mineral oil) is added in small portions to a suspension of N-,N′-di-Cbz-guanidine (1.65 g, 5.0 mmol) in anhydrous THF (20 ml) at −45° C. under an atmosphere of argon. After the addition is completed, the mixture is stirred for 1 h at −45° C. Benzyl chloroformate (0.82 ml, 5 mmol) is added, the mixture is allowed to warm up to room temperature and stirred overnight. The solvent is removed under reduced pressure and the residue is dissolved in a mixture of dichloromethane (50 ml) and water (25 ml). The phases are separated and the aqueous layer is extracted twice with dichloro methane (50 ml each). The extracts are combined, washed with 1N hydrochloric acid and water and dried with magnesium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is purified by flash chromatography on silica gel (eluent: dichloromethane-ethyl ether 98:2). N-,N′-N″-tri-Cbz-guanidine (2.07 g, 90%) is obtained as a white powder: mp: 111-112° C.;1H NMR (360 MHz, DMSO-d6) δ 10.55, (s, 2H), 7.36 (s, 10H), 5.22 (br s, 6H); FAB-MS m/e (relative intensity) 506 (5, M-H++2Na+), 484 (100, M+Na+), 462 (24, M+H+); Anal. Calc. for C, 65.07%; H, 5.02%;.N, 9.11%; Found: C, 64.89%; H, 4.74%;.N, 8.82%.
- A solution of anhydrous methanol (0.04 ml, 1.0 mmol), N-,N′-,N″-tri-Boc-guanidine (1.80 g, 5.0 mmol), and triphenylphoshine (393 mg, 1.5 mmol) in anhydrous THF (50 ml) is cooled to −5° C. under an atmosphere of argon. Diethylazodicarboxylate (DEAD, 0.22 ml, 1.5 mmol) is added dropwise at a rate such that the reaction mixture is completely colorless before addition of the next drop. After the addition is completed, the reaction mixture is refluxed for 15h. The solution is then cooled to room temperature, and hexanes (50 ml) is added. A precipitate of excess N-,N′-,N″-tri-Boc-guanidine forms which is collected by filtration on a Buechner-funnel and washed with a mixture of THF/hexanes 1:1. The filtrate is concentrated under reduced pressure and the product (colorless oil, 182 mg, 49%) isolated by flash chromatography on silica gel (eluent: dichloromethane-ethyl ether 98:2):1H NMR (360 MHz, DMSO-d6) δ 10.17 (s, 1H), 2.94 (s, 3H), 1.43-1.36 (27H); FAB-MS m/e (relative intensity) 396 (100, M+Na+).374 (91, M+H+).
- A solution of S—N-Cbz-2-amino-5-hydroxy-valeric acid methyl ester (0.56 g, 2.0 mmol), N-,N′-,N″-tri-Boc-guanidine (3.59, 10.0 mmol), and triphenylphoshine (0.79 g, 3.0 mmol) in anhydrous THF (100 ml) is cooled to −5° C. under an atmosphere of argon. Diethylazodicarboxylate (DEAD, 0.45 ml, 3.0 mmol) is added dropwise at a rate such that the reaction mixture is completely colorless before addition of the next drop. After the addition is completed, the reaction mixture is stirred for 18 h at 45° C. The solution is then cooled to room temperature, and hexanes (100 ml) is added. A precipitate of excess N-,N′-N″-tri-Boc-guanidine forms which is collected by filtration on a Buechner-funnel and washed with a mixture of THF/hexanes 1:1. The filtrate is concentrated under reduced pressure and the product (colorless oil, 0.87 g, 70%) isolated by flash chromatography on silica gel (eluent: dichloromethane-ethyl ether 9:1): 1H NMR (360 MHz, DMSO-d6) δ 10.18 (s, 1H), 7.72 (d, 1H, J=7.9 Hz), 7.40-7.26 (m, 5H), 5.01 (s, 2H), 4.03-3.94 (m, 1H), 3.60 (s, 3H), 3.45 (t, 2H, J=5.8 Hz), 1.73-1.45 (m, 4H), 1.39 (s, 18H), 1.37 (s, 9H); FAB-MS m/e 623 (M+H+).
- A solution of S—N-Cbz-2-amino-5-hydroxy-valeric acid methyl ester (143 mg, 0.4 mmol), N-methyl-N-,N′-,N″-tri-Boc-guanidine (150 mg, 0.4 mmol), and triphenylphoshine (105 mg, 0.4 mmol) in anhydrous THF (2 ml) is cooled to −5° C. Diethylazodicarboxylate (DEAD, 0.06 ml, 0.38 mmol) is added dropwise at a rate such that the reaction mixture is completely colorless before addition of the next drop. After the addition is completed, the reaction mixture is refluxed for 3 h. The solvent is removed under reduced pressure and the product (colorless oil, 181 mg, 63%) is isolated by flash chromatography on silica gel (eluent: ethyl acetate-hexanes 1:3):1H NMR (360 MHz, DMSO-d6) δ 7.80 (d, 2H, J=7.9 Hz), 7.39-7.28 (m, 10H), 5.10 (s, 2H), 5.06-4.94 (m, 2H), 4.11-4.00 (m, 1H), 3.53-3.44 (m, 2H), 2.89 (s, 3H), 1.75-1.50 (m, 4H), (1.40-1.34 (27H); FAB-MS z/e 845 (M+Cs+).
- 1,4-Dioxane (50 ml) is added to a solution of guanidine hydrochloride (2.39 g, 25 mmol) and sodium hydroxide (4.0 g, 0.1 mol) in water (25 ml) and the resulting mixture is cooled to 0° C. Di-tert-butyl-pyrocarbonate (12.0 g, 55 mmol) is added in one portion while stirring. The reaction mixture is allowed to warm to room temperature within 2 h. After stirring for 20 h the mixture is concentrated in vacuo to one third of its original volume. The resulting suspension is diluted with water (50 ml) and extracted three times with ethyl acetate (5 ml each). The combined extracts are washed with 10% citric acid, water and brine and dried with magnesium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is purified by flash chromatography on silica gel (eluent: dichloromethane-methanol 97:3). N-,N′-di-Boc-guanidine (3.84 g, 59%) is obtained as a colorless powder: mp: 144° C.;1H NMR (360 MHz, DMSO-d6) δ 10.42 (br s, 1H), 8.47 (br s, 2H), 1.39 (s, 18H); FAB-MS m/e (relative intensity) 260 (50, M+H+), 204 (48), 148 (100); Anal. Calc. for: C, 50.95%; H, 8.16%;.N, 16.21%; Found: C, 50.83%; H, 8.04%;.N, 16.26%.
- A solution of N-,N′-di-Boc-guanidine (0.52 g, 2.0 mmol) and triethyl amine (0.29 ml) in anhydrous dichloromethane (10 ml) is cooled to −78° C. under an atmosphere of argon. Triflic anhydride (0.35 ml, 2.1 mmol) is added dropwise at a rate such that reaction temperature does not exceed −65° C. After the addition is completed, the mixture is allowed to warm to room temperature within 4 h. The solution is transferred to a separation funnel, washed with 2M sodium bisulfate and water and dried with anhydrous sodium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is purified by flash chromatography on silica gel (eluent: dichloromethane). N-N′-Di-Boc-N′″-trifluoromethanesulfonyl-guanidine (686 mg, 88%) is obtained as pale yellow crystals. The product can be further purified by recrystallization from hexanes: mp: 115° C.;1H NMR (360 MHz, DMSO-d6) δ 11.45 (br s, 2H), 1.45 (s, 18H). FAB-MS m/e (relative intensity) 414 (16, M+Na+), 392 (13, M+H+), 336 (43), 280 (100), 236 (9); Anal. Calc. for C, 36.83%; H, 5.15%;.N, 10.74%; F, 14.56%; S, 8.19%; Found: C, 36.93%; H, 5.21%;.N, 10.66%; F, 14.80%; S, 8.33%.
- Dichloromethane (80 ml) is added to a solution of guanidine hydrochloride (3.82 g, 40 mmol) and sodium hydroxide (8 g, 0.2 mol) in water (40 ml) and the resulting mixture is cooled to 0° C. Benzyloxycarbonyl chloride (17.1 ml, 120 mmol) is added dropwise with vigorous stirring over a period of 45 min. After the addition is completed, stirring is continued for 20 h at 0° C. The mixture is diluted with dichloromethane (100 ml), the layers are separated and the aqueous layer is extracted with dichloromethane (100 ml). The extracts are combined, washed with water and dried with magnesium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is recrystallized from methanol. N-,N′-Di-Cbz-guanidine (9.85 g, 75%) is obtained as colorless crystals: mp: 149-150° C.; H NMR (360 MHz, DMSO-d6) δ 10.88 (br s, 1H), 8.67 (br s, 2H), 7.40-7.25 (m, 10H), 5.10 (s, 4H); Anal. Calc. for C, 62.38%; H, 5.23%;.N, 12.84%. Found: C, 62.26%; H, 5.01%;.N, 12.79%.
- Sodium hydride (400 mg, 60 dispersion in mineral oil) is added to a solution of N-,N′-di-Cbz-guanidine (1.65 g, 5.0 mmol) in anhydrous chlorobenzene (50 ml) at 0° C. under an atmosphere of argon. After stirring for 1 h at 0° C., the mixture is cooled to −45° C. Triflic anhydride (0.82 ml, 5 mmol) is added, the mixture is allowed to warm up to room temperature and stirred overnight. The solvent is removed under reduced pressure and the residue is dissolved in a mixture of ethyl acetate (100 ml) and 2M sodium bisulfate (25 ml). The phases are separated and the organic layer is washed with water and brine and dried with magnesium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is purified by flash chromatography on silica gel (eluent: dichloromethane-ethyl ether 95:5). N-N′-Di-Cbz-N′″-trifluoromethanesulfonyl guanidine (1.58 g, 69%) is obtained as a pale oil that crystallizes in vacuo: mp: 74-75° C.;1H NMR (360 MHz, DMSO-d6) δ 11.55 (br s, 2H), 7.45-7.28 (m, 10H), 5.20 (s, 4H); Electrospray-MS m/le (relative intensity) 498 (30, M+K+), 482 (100, M+Na+), 460 (2, M+H+); Anal. Calc. for C, 47.06%; H, 3.51%;.N, 9.15%; F, 12.41%; S, 6.98%; Found: C, 47.37%; H, 3.35%;.N, 8.67%; F, 12.79%; S, 6.92%.
- 1,4-Dioxane (20 ml) is added to a solution of guanidine hydrochloride (0.96 g, 10 mmol) and sodium hydroxide (0.8 g, 20 mmol) in water (10 ml) and the resulting mixture is cooled to 0° C. Benzyloxycarbonyl chloride (1.1 ml, 7.7 mmol) is added dropwise with vigorous stirring over a period of 10 min. After the addition is completed, the ice-bath is removed and stirring is continued for 1 h at room temperature. The mixture is concentrated in vacuo to one third of its original volume and extracted three times with ethyl acetate (20 ml each). The combined extracts are washed with brine (20 ml) and dried with anhydrous sodium sulfate. After filtering and removal of the solvent under reduced pressure N-Cbz-guanidine (1.31 g, 88%) is obtained as a white powder: mp: 120-122° C.;1H NMR (360 MHz, DMSO-d6) δ 7.35-7.25 (m, 5H), 6.88 (br s, 4H), 4.95 (s, 2H); Electrospray-MS m/e 194 (M+H+).
- A solution of di-tertbutyl-pyrocarbonate (1.32 g, 6.05 mmol) in acetone (5 ml) is added in one portion to a stirred solution of N-Boc-N′-Cbz-guanidine (1.30 g, 6.73 mmol) and triethyl amine (0.94 ml) in acetone (15 ml). After stirring for 48 h at room temperature the solvent is removed under reduced pressure and the resulting residue is dissolved in a mixture of ethyl acetate (100 ml) and water (50 ml). The phases are separated and the organic layer is washed with 2M sodium bisulfate, water and brine and dried with anhydrous sodium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is purified by flash chromatography on silica gel (eluent: dichloromethane-ethyl ether 9:1). N-Boc-N′-Cbz-guanidine (1.44 g, 82%) is obtained as a white powder: mp: 125-126° C.;1H NMR (360 MHz, DMSO-d6) δ 10.59 (br s, 1H), 8.69 (br s, 1H), 8.50 (br s, 1H), 7.40-7.25 (m, 5H), 5.04 (s, 2H), 1.42 (s, 9H).
- A solution of N-Boc-N′-Cbz-guanidine (586 mg, 2.0 mmol) and triethyl amine (0.42 ml) in anhydrous dichloromethane (20 ml) is cooled to −78° C. under an atmosphere of argon. Triflic anhydride (0.42 ml, 2.5 mmol) is added dropwise at rate such that reaction temperature does not exceed −65° C. After the addition is completed, the mixture is allowed to warm to room temperature within 4 h. The solution is transferred to a separation funnel, washed with 2M sodium bisulfate and water and dried with anhydrous sodium sulfate. After filtering and removal of the solvent under reduced pressure the crude product is purified by flash chromatography on silica gel (eluent: dichloromethane). N-Boc-N′-Cbz-N″-trifluoromethanesulfonyl-guanidine (699 mg, 82%) is obtained as a pale oil that crystallizes upon drying in vacuo: mp: 95-97° C.;1H NMR (360 MHz, DMSO-d6) δ 11.49 (br s, 1H), 11.17 (br s, 1H), 7.40 (m, 5H), 5.21 (s, 1H), 1.43 (s, 9H); FAB-MS m/e (relative intensity) 448 (23, M+Na+), 426 (44, M+H+), 329 (5), 370 (100), 348 (15), 326 (15).
- N-N′-Di-Boc-N″-trifluoromethanesulfonyl-guanidine (235 mg, 0.6 mmol) is added to a solution of pyrrolidine (0.042 ml, 0.5 mmol) and triethyl amine (0.083 ml) in chloroform (1 ml). After stirring for 4 h at room temperature, the product is isolated by flash chromatography on silica gel (eluent: ethyl acetate-hexane 2:3). The product (146 mg, 93%) is obtained as a colorless oil that crystallizes in vacuo: mp: 88-91° C.;1H NMR (360 M CDCl3) δ 3.58-3.53 (m, 4H), 1.90-1.83 (m, 4H), 1.46 (s, 18H); FAB-MS m/e (relative intensity) 649 (13, 2M+Na+), 627 (5, 2M+H+), 336 (29, M+Na+), 314 (100, M+H+), 258 (28), 202 (94).
- Aniline (0.055 ml, 0.6 mmol) is added to a solution of N-N′-di-Cbz-N″-trifluoromethanesulfonyl-guanidine in chloroform and the mixture is stirred for 1 h at room temperature. The solvent is removed under reduced pressure the residue is dissolved in ethyl ether (10 ml). The solution is washed with 10% citric acid, water and brine, and dried with magnesium sulfate. After filtration and removal of the solvent under reduced pressure N-N′-di-Boc-N″-phenyl-guanidine (198 mg, 98%) is obtained as a colorless oil that crystallizes upon drying in vacuo: mp: 105-108° C.;1H NMR (360 MHz, DMSO-d6) δ 11.34 (br s, 1H), 9.99 (s, 1H), 7.56-7.11 (m, 15H), 5.23 (s, 2H), 5.02(s, 1H). FAB-MS m/e (relative intensity) 426 (M+Na+), 404 (M+H+).
- The procedures of the invention as described above are to be understood as exemplary and do not indicate limitations of the invention, which is to be understood as limited only by the scope of the following claims.
Claims (21)
3. The protected molecules of claims 1-2 wherein the urethane protecting groups are selected from the group consisting of
(a) tert-butyloxycarbonyl (Boc)
(b) benzyloxycarbonyl (Cbz),
(c) allyloxycarbonyl (Alloc)
(d) 2,2,2-trichloroethyloxycarbonyl (Troc),
(e) 2-chlorobenzyloxycarbonyl; and
(f) 4-methoxy-benzyloxycarbonyl (Moz).
4. N-,N′-,N″-Tri-tert-butyloxycarbonyl-guanidine
5. N-,N′-,N″-Tri-benzyloxycarbonyl-guanidine
6. N-Methyl-N-,N′-,N″-tri-tert-butyloxycarbonyl-guanidine
7. N-Methyl-N-,N′-,N″-tri-tert-benzyloxycarbonyl-guanidine
10. N-N′-Di-Boc-N″-trifluoromethanesulfonyl-guanidine
11. N-N′-Di-Cbz-N″-Trifluoromethanesulfonyl-guanidine
12. N-Boc-N′-Cbz-N″-Trifluoromethanesulfonyl-guanidine
13. A method for guanidinylation comprising reacting a protected guanidine of the structure
wherein P1, P2 and P3 are the same or different urethane groups, with an alcohol of the structure
15. A method for preparing arginine homologs, comprising reacting a protected guanidine of the structure
16. A method for guanidinylating amines, comprising reacting a protected guanidine of the structure
wherein P1, P2 and P3 are the same or different urethane groups, and R1 is a substituted or unsubstituted alkyl group, and a primary or secondary amine of the structure
wherein R2 and R3 are independently H, or a substituted or unsubstitued alkyl group, or an amino acid or a polypeptide, or R2 and R3 are part of a cyclic structure as in piperidine, pyrrolidine, or morpholine, to yield a product of the structure
18. Guanidinylated compounds prepared by the method of any one of claims 15-17.
19. Guanidinylated compounds prepared by reacting a guanidinylating reagent selected from the group consisting of
N-N′-di-Boc-N″-trifluoromethanesulfonyl-guanidine,
N-N′-di-Cbz-N″-trifluoromethanesulfonyl-guanidine, and
N-Boc-N′-Cbz-N″-trifluoromethanesulfonyl-guanidine
with a primary amine.
20. Guanidinylated compounds prepared by reacting a guanidinylating reagent selected from the group consisting of
N-N′-di-Boc-N″-trifluoromethanesulfonyl-guanidine,
N-N′-di-Cbz-N″-trifluoromethanesulfonyl-guanidine, and
N-Boc-N′-Cbz-N″-trifluoromethanesulfonyl-guanidine
with a secondary amine.
21. A method for the solid phase synthesis of a peptide comprising one or more arginine homologs, comprising the steps of:
(a) assembling a sequence (Xaa)n of amino acids on a solid phase peptide synthesis resin, where Xaa denotes any appropriately protected amino acid.
(b) attaching an amino acid having the structure
wherein Q is Boc or Fmoc and P is any protecting group that can be selectively removed, and n=0-3, to the amino terminus of the product of step (a);
(c) coupling any sequence of suitably protected amino acids to the amino terminus of the product of step (b);
(d) selectively removing all the protecting groups P as defined in (b) from the product of step (c)
(e) reacting a protected guanidine having the structure
with the product of step (d) to guanidinylate all unprotected amino functions present; and
(f) removing all protecting groups and cleaving the peptide from the resin to yield the product
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/137,119 US20030055214A1 (en) | 1997-05-22 | 2002-04-30 | Guanidinylation reagents |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/861,942 US6072075A (en) | 1997-05-22 | 1997-05-22 | Guanidinylation reagents |
US09/452,895 US6380358B1 (en) | 1997-05-22 | 1999-12-01 | Guanidinylation reagents |
US10/137,119 US20030055214A1 (en) | 1997-05-22 | 2002-04-30 | Guanidinylation reagents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/452,895 Continuation US6380358B1 (en) | 1997-05-22 | 1999-12-01 | Guanidinylation reagents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030055214A1 true US20030055214A1 (en) | 2003-03-20 |
Family
ID=25337171
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/861,942 Expired - Lifetime US6072075A (en) | 1997-05-22 | 1997-05-22 | Guanidinylation reagents |
US09/452,895 Expired - Fee Related US6380358B1 (en) | 1997-05-22 | 1999-12-01 | Guanidinylation reagents |
US10/137,119 Abandoned US20030055214A1 (en) | 1997-05-22 | 2002-04-30 | Guanidinylation reagents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/861,942 Expired - Lifetime US6072075A (en) | 1997-05-22 | 1997-05-22 | Guanidinylation reagents |
US09/452,895 Expired - Fee Related US6380358B1 (en) | 1997-05-22 | 1999-12-01 | Guanidinylation reagents |
Country Status (15)
Country | Link |
---|---|
US (3) | US6072075A (en) |
EP (1) | EP0983232B1 (en) |
JP (1) | JP2002502378A (en) |
KR (1) | KR20010012732A (en) |
AT (1) | ATE227705T1 (en) |
AU (1) | AU736072B2 (en) |
BR (1) | BR9809859A (en) |
CA (1) | CA2288196A1 (en) |
DE (1) | DE69809412D1 (en) |
HU (1) | HUP0003978A3 (en) |
IL (1) | IL132773A0 (en) |
NO (1) | NO995693L (en) |
PL (1) | PL336996A1 (en) |
SK (1) | SK157099A3 (en) |
WO (1) | WO1998052917A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525182B1 (en) * | 2000-01-21 | 2003-02-25 | Regents Of The University Of California | Guanidinylation, guanidinoglycosides, uses, and methods of assaying their activity |
FR2822463B1 (en) | 2001-03-21 | 2004-07-30 | Lipha | BICYCLIC GUANIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
US20060264608A1 (en) * | 2001-08-03 | 2006-11-23 | Wender Paul A | Bi-directional synthesis of oligoguanidine transport agents |
US7067698B2 (en) * | 2001-08-03 | 2006-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bi-directional synthesis of oligoguanidine transport agents |
PL195917B1 (en) * | 2001-10-31 | 2007-11-30 | Inst Farmaceutyczny | Novel peptides - analogues of a human hormone responsible for release of the growth hormone |
US7022214B2 (en) * | 2004-01-21 | 2006-04-04 | Bio-Rad Laboratories, Inc. | Carrier ampholytes of high pH range |
JP4777225B2 (en) * | 2006-12-04 | 2011-09-21 | キヤノン株式会社 | Discharge liquid and discharge method |
WO2013070808A1 (en) | 2011-11-07 | 2013-05-16 | Feng Tian | Peptide-based compounds as inhibitors of neurotransmitter secretion |
US10202337B2 (en) * | 2014-03-28 | 2019-02-12 | Kaneka Corporation | Method for producing tri-carbobenzoxy-arginine |
CN107266610A (en) * | 2017-07-27 | 2017-10-20 | 山东百玛海洋生物科技有限公司 | The application of guanidinated chitosan derivative and nanoparticle |
CN107236056A (en) * | 2017-07-27 | 2017-10-10 | 山东百玛海洋生物科技有限公司 | Guanidinated chitosan derivative, nanoparticle and preparation method thereof |
CN111163807A (en) * | 2017-09-19 | 2020-05-15 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Lipophilic peptide prodrugs |
CN114907241B (en) * | 2021-02-09 | 2024-05-17 | 中宏鑫投资控股(深圳)有限公司 | Guanidine compound containing fluorosulfonyl group, and preparation method and application thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1677235A (en) * | 1928-07-17 | Balph v | ||
US1681806A (en) * | 1928-08-21 | Ments | ||
US1953494A (en) * | 1926-08-26 | 1934-04-03 | Ig Farbenindustrie Ag | Process of preparing substituted guanidines |
US1795738A (en) * | 1927-09-12 | 1931-03-10 | Scheringkahlbaum A G | Method of producing substituted guanidines |
US2898369A (en) * | 1956-02-23 | 1959-08-04 | Mcneilab Inc | N,n,n',n'' tetraethyl guanidine and its acid addition salts |
US3062804A (en) * | 1957-03-08 | 1962-11-06 | Sterling Drug Inc | Peptide synthesis and intermediates therefor |
US3062805A (en) * | 1957-03-08 | 1962-11-06 | Sterling Drug Inc | Peptide synthesis and intermediates therefor |
US3117994A (en) * | 1959-12-03 | 1964-01-14 | Monsanto Canada Ltd | Nu, nu', nu'-trisubstituted guanidines |
US3301755A (en) * | 1962-04-18 | 1967-01-31 | Ciba Geigy Corp | Allylic guanidines |
US3479437A (en) * | 1963-08-26 | 1969-11-18 | Stauffer Chemical Co | Guanidine complexes as fungicides |
US3320229A (en) * | 1963-08-26 | 1967-05-16 | Stauffer Chemical Co | Complexes of guanidines with completely halogenated acetones |
CH426863A (en) * | 1963-08-30 | 1966-12-31 | Sandoz Ag | Process for the preparation of arginine-containing polypeptides |
US3609164A (en) * | 1968-03-27 | 1971-09-28 | Tanabe Seiyaku Co | Process for preparing {11 -butoxycarbonyl compounds |
US3551490A (en) * | 1968-05-21 | 1970-12-29 | American Cyanamid Co | Method for preparing tetramethyl-guanidine |
US3646029A (en) * | 1968-09-25 | 1972-02-29 | Monsanto Co | Piperazino methyl 1 3 diarylguandines |
IL38933A0 (en) * | 1971-03-17 | 1972-05-30 | Ciba Geigy Ag | New carbamates,their manufacture and their use in plant protection |
DE2315271C3 (en) * | 1973-03-27 | 1975-09-11 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | L-norleucine-13-motiline, process for its preparation and agent containing the same |
US4014915A (en) * | 1975-04-22 | 1977-03-29 | Fujisawa Pharmaceutical Co., Ltd. | Oxime carbonates |
DE2544348C3 (en) * | 1975-10-03 | 1979-12-13 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | L-leucine-13-motiline, process for its preparation and agent containing the same |
US4358613A (en) * | 1979-12-26 | 1982-11-09 | General Electric Company | Process for the preparation of substituted guanidines |
FR2509724B1 (en) * | 1981-07-15 | 1985-10-25 | Centre Nat Rech Scient | NOVEL HIGHLY STERICALLY CONTAINED GUANIDINES AND METHODS FOR THEIR PREPARATION |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
JPH0692357B2 (en) * | 1989-10-18 | 1994-11-16 | キヤノン株式会社 | Toner for developing electrostatic image containing guanidine compound and guanidine compound |
US5262568A (en) * | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
EP0646573A1 (en) * | 1993-09-30 | 1995-04-05 | Hoechst Aktiengesellschaft | Preparation of protected and unprotected guanidino-substituted carboxylic acids |
-
1997
- 1997-05-22 US US08/861,942 patent/US6072075A/en not_active Expired - Lifetime
-
1998
- 1998-05-21 HU HU0003978A patent/HUP0003978A3/en unknown
- 1998-05-21 SK SK1570-99A patent/SK157099A3/en unknown
- 1998-05-21 BR BR9809859-4A patent/BR9809859A/en not_active Application Discontinuation
- 1998-05-21 DE DE69809412T patent/DE69809412D1/en not_active Expired - Lifetime
- 1998-05-21 JP JP55074698A patent/JP2002502378A/en active Pending
- 1998-05-21 KR KR1019997010693A patent/KR20010012732A/en not_active Application Discontinuation
- 1998-05-21 CA CA002288196A patent/CA2288196A1/en not_active Abandoned
- 1998-05-21 IL IL13277398A patent/IL132773A0/en unknown
- 1998-05-21 PL PL98336996A patent/PL336996A1/en unknown
- 1998-05-21 AU AU77984/98A patent/AU736072B2/en not_active Ceased
- 1998-05-21 AT AT98926066T patent/ATE227705T1/en not_active IP Right Cessation
- 1998-05-21 EP EP98926066A patent/EP0983232B1/en not_active Expired - Lifetime
- 1998-05-21 WO PCT/US1998/010669 patent/WO1998052917A2/en not_active Application Discontinuation
-
1999
- 1999-11-19 NO NO995693A patent/NO995693L/en not_active Application Discontinuation
- 1999-12-01 US US09/452,895 patent/US6380358B1/en not_active Expired - Fee Related
-
2002
- 2002-04-30 US US10/137,119 patent/US20030055214A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL336996A1 (en) | 2000-07-31 |
NO995693L (en) | 2000-01-18 |
JP2002502378A (en) | 2002-01-22 |
US6072075A (en) | 2000-06-06 |
WO1998052917A2 (en) | 1998-11-26 |
EP0983232A2 (en) | 2000-03-08 |
EP0983232B1 (en) | 2002-11-13 |
HUP0003978A3 (en) | 2002-03-28 |
BR9809859A (en) | 2000-12-19 |
KR20010012732A (en) | 2001-02-26 |
ATE227705T1 (en) | 2002-11-15 |
CA2288196A1 (en) | 1998-11-26 |
WO1998052917A3 (en) | 1999-04-22 |
SK157099A3 (en) | 2000-06-12 |
US6380358B1 (en) | 2002-04-30 |
AU736072B2 (en) | 2001-07-26 |
DE69809412D1 (en) | 2002-12-19 |
NO995693D0 (en) | 1999-11-19 |
IL132773A0 (en) | 2001-03-19 |
HUP0003978A2 (en) | 2001-03-28 |
AU7798498A (en) | 1998-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6380358B1 (en) | Guanidinylation reagents | |
WO2019069978A1 (en) | Method for producing peptide compound | |
JP5789254B2 (en) | Lysine compounds and their use in site-selective and functional group-selective modification of peptides and proteins | |
WO2010081014A1 (en) | Novel 4-fluoropyrrolidine-2-carbonyl fluoride compounds and their preparative methods | |
DK154437B (en) | METHOD FOR PREPARING THE PENTAPEPTID H-ARG-X-Z-Y-TIRE-R BY SOLUTION SYNTHESIS | |
JP2018515512A (en) | Method for preparing nitrogen mustard derivatives | |
Sureshbabu et al. | New and simple synthesis of acid azides, ureas and carbamates from carboxylic acids: application of peptide coupling agents EDC and HBTU | |
US4954616A (en) | Use of guanidine-related compounds comprising a substituted tetraphenylborate ion in solution phase peptide synthesis | |
US20140142279A1 (en) | Method for peptide synthesis | |
ES2201271T3 (en) | SOLID PHASE TECHNIQUE FOR THE PREPARATION OF AMIDAS. | |
EP4083054A1 (en) | Method for producing pna oligomer in solution process | |
US6492541B2 (en) | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | |
MXPA99010786A (en) | Guanidinylation reagents | |
JP3067845B2 (en) | Method for producing N-alkylsulfonylaminosulfonylurea | |
Tantry et al. | 1-(t-Butyldimethylsilyloxy) benzotriazole (TBDMS-OBt): A new and novel reagent for the synthesis of peptides | |
WO2024164992A1 (en) | Catalyst for sp3-carbon-hydrogen-bond primary amination reaction, and method for preparing primary amine compound | |
CZ407099A3 (en) | Guanidinizing agent and guanidization process | |
US6664410B1 (en) | Solid phase nitrile synthesis | |
US20040171079A1 (en) | Combinatorial active compound synthesis and its intermediates | |
Yao et al. | Study on the dipeptide vinyl sulfonamide derivatives as proteasome inhibitor | |
Sureshbabu et al. | Pentafluorophenyl-(tert-butoxycarbonylamino) methylcarbamates: Synthesis, isolation and application to the synthesis of ureidopeptides | |
JPH0327353A (en) | Preparation of sulfonium compound | |
JPH0641088A (en) | Production of sulfonylurea | |
MXPA98003661A (en) | Acids sulfonilaminocarboxili | |
WO2000053545A1 (en) | Process for the synthesis of dihydropyridones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |